# Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

> **NCT05653661** · PHASE1 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Unresectable Melanoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Nab-paclitaxel/Danburstotug Complex AP160

## Key facts

- **NCT ID:** NCT05653661
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-30
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor business considerations
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653661, "Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05653661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*